MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2025)
MapLight Therapeutics (MPLT) reported Income from Continuing Operations of 81207000.0 for Q4 2025, down 276.34% on a YoY basis from 46050948.62 in Q4 2024, and down 138.36% sequentially from 34069000.0 in Q3 2025.
MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Income from Continuing Operations data on file, last reported at 81207000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 276.34% year-over-year to 81207000.0; the trailing twelve-month figure through Dec 2025 stood at 156967000.0 (changed N/A YoY), and the FY2025 full-year result was 176190000.0, down 93.77% from the prior year.
- Income from Continuing Operations retreated to 81207000.0 in Q4 2025, from 34069000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 20113000.0 in Q3 2024 to a low of 81207000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | -81.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -81.21 Mn |
| Sep 30, 2025 | -34.07 Mn |
| Dec 31, 2024 | -21.58 Mn |
| Sep 30, 2024 | -20.11 Mn |